Key Takeaways
- Artis BioSolutions has launched after acquiring Landmark Bio, a development and manufacturing firm.
- Landmark will maintain independence while operating under Artis, focusing on reducing costs in genetic therapies.
- Artis is backed by Oak HC/FT and will serve as a contract development and manufacturing organization for advanced therapies.
Artis BioSolutions Launches with Landmark Bio Acquisition
US biotech company Artis BioSolutions has officially entered the market following its acquisition of Landmark Bio, a translational development and manufacturing firm created through collaborations between academic and industry stakeholders. With this acquisition, Landmark will continue to operate from its headquarters in Watertown, Massachusetts, maintaining its existing team and facilities.
The integration aims to enhance the efficiency of developing genetic therapies, a critical area where costs and complexity often pose challenges. Artis BioSolutions intends to streamline the pathway for these therapies to reach patients, thereby increasing accessibility and affordability.
Artis is supported by Oak HC/FT, a healthcare investment firm, and is set to function as a contract development and manufacturing organization (CDMO) specializing in advanced therapies. This new venture is poised to capitalize on the growing demand for personalized medicine, where genetic therapies are becoming increasingly prominent in treatment options.
Overall, the acquisition marks a significant step for Artis as it seeks to play a vital role in the biotechnology landscape, particularly in the realm of genetic therapies. The company’s commitment to innovation and efficiency in this field could potentially transform how these therapies are developed and delivered to patients in need.
The content above is a summary. For more details, see the source article.